Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproate Neuroprotection in Bipolar Disorder
NCT00431522Phase 4Completed
- Sponsor
- Sanofi
- Start
- Dec 2004
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of valproic acid in bipolar disorder (BD) (2 arms), sponsored by Sanofi. Primary endpoints: Regional N-acetyl aspartate levels at 6 weeks and Total and Regional Gray Matter Volume at 6 weeks. Started Dec 2004; status: completed.
02
Drugs
valproic acid
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00431522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431522.